{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:28:03Z","timestamp":1773192483850,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"crossref","award":["PID2023-147765OB-C21"],"award-info":[{"award-number":["PID2023-147765OB-C21"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"crossref","award":["-C22"],"award-info":[{"award-number":["-C22"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n Roviralta"},{"name":"Spanish Ministry of Science, Innovation and Universities","award":["FPU23\/01618"],"award-info":[{"award-number":["FPU23\/01618"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Antimicrobial peptides (AMPs) represent a promising class of therapeutics with diverse biological functions, including antibacterial, anti-fungal, anti-parasitic and anti-tumoral activities. Previous works demonstrated the successful repurposing of the two synthetic AMPs 19-2.5 and 19-4LF for cutaneous leishmaniasis, when the compounds were administered in solution on skin lesions caused by Leishmania major in a BALB\/c mouse model. In this research project, we assessed the activity of 19-4LF, 19-2.5, and their hybrid 19-2.5LF derivative when formulated as a cream for topical administration in the same animal model. Methods: The peptides were formulated in DAC cream and applied to the wound of BALB\/C mice for 30 days. Lesion progression was monitored using a digital caliper. Parasite burden was measured by qPCR. Parasite viability was assessed using MTT and microscopy imaging assays. Results: The three peptides in cream formulation succeeded in reducing the skin lesion. Peptide 19-4LF was the most potent, followed by 19-2.5LF and then 19-2.5. In addition, 19-4LF was able to significantly reduce the parasite burden in the skin lesions of infected mice, as measured by quantifying L. major Lm18S ribosomal gene mRNA levels using qPCR. Moreover, when combined, the peptides exhibited synergistic effects on L. major promastigotes and significantly reduced the number of amastigotes in infected macrophages. Conclusions: These studies support the approach of repurposing these AMPs as antileishmanial drugs and identify 19-4LF as a lead candidate for further studies. While historical barriers to peptide therapeutics included high production costs, recent advancements in biological fermentation and synthesis strategies have significantly improved their economic viability. Furthermore, the use of nanotechnology delivery systems can reduce the required dosage, further making peptide therapy a sustainable option for neglected diseases, including leishmaniasis.<\/jats:p>","DOI":"10.3390\/pharmaceutics18030332","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:06:52Z","timestamp":1773054412000},"page":"332","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leishmanicidal Action of the Peptides 19-4LF, 19-2.5 and 19-2.5LF Topically Administered on Cutaneous Lesions Caused by Leishmania major"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-095X","authenticated-orcid":false,"given":"Rima","family":"El-Dirany","sequence":"first","affiliation":[{"name":"Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1465-6011","authenticated-orcid":false,"given":"Paolo","family":"Ginatta","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-8121","authenticated-orcid":false,"given":"Celia","family":"Fern\u00e1ndez-Rubio","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2167-092X","authenticated-orcid":false,"given":"Aroia","family":"Burguete-Mikeo","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-6513","authenticated-orcid":false,"given":"Esther","family":"Larrea","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"},{"name":"Unit of Translational Medicine, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-451X","authenticated-orcid":false,"given":"Guillermo","family":"Martinez-de-Tejada","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-7316","authenticated-orcid":false,"given":"Paul A.","family":"Nguewa","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), University of Navarra, c\/Irunlarrea 1, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"127822","DOI":"10.1016\/j.micres.2024.127822","article-title":"Antimicrobial Peptides: Opportunities and Challenges in Overcoming Resistance","volume":"286","author":"Bucataru","year":"2024","journal-title":"Microbiol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"El-Dirany, R., Fern\u00e1ndez-Rubio, C., Pe\u00f1a-Guerrero, J., Moreno, E., Larrea, E., Espuelas, S., Abdel-Sater, F., Brandenburg, K., Mart\u00ednez-de-Tejada, G., and Nguewa, P. (2022). Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112528"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejps.2018.01.022","article-title":"Peptide Drug Stability: The Anti-Inflammatory Drugs Pep19-2.5 and Pep19-4LF in Cream Formulation","volume":"115","author":"Kuhlmann","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1128\/AAC.00534-10","article-title":"New Antiseptic Peptides to Protect against Endotoxin-Mediated Shock","volume":"54","author":"Thomas","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Heinbockel, L., Marwitz, S., Barcena Varela, S., Ferrer-Espada, R., Reiling, N., Goldmann, T., Gutsmann, T., Mier, W., Sch\u00fcrholz, T., and Dr\u00f6mann, D. (2015). Therapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal Sepsis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133291"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103546","DOI":"10.1016\/j.micpath.2019.103546","article-title":"Antimicrobial Peptides Pep19\u20132.5 and Pep19-4LF Inhibit Streptococcus Mutans Growth and Biofilm Formation","volume":"133","author":"Jannadi","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdermsci.2018.07.005","article-title":"Combination of Paromomycin plus Human Anti-TNF-\u03b1 Antibodies to Control the Local Inflammatory Response in BALB\/Mice with Cutaneous Leishmaniasis Lesions","volume":"92","author":"Schwartz","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal Research: Reporting in Vivo Experiments: The ARRIVE Guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1128\/AAC.00997-15","article-title":"Leishmanicidal Activities of Novel Methylseleno-Imidocarbamates","volume":"59","author":"Campbell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123173","DOI":"10.1016\/j.carbpol.2024.123173","article-title":"Solution Blow Spun Polymeric Nanofibres Embedding Cyclodextrin Complexes of Miltefosine: An Approach to the Production of Sprayable Dressings for the Treatment of Cutaneous Leishmaniasis","volume":"353","author":"Dirany","year":"2025","journal-title":"Carbohydr. Polym."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1111\/bph.14425","article-title":"Antimicrobial Endotoxin-Neutralizing Peptides Promote Keratinocyte Migration via P2X7 Receptor Activation and Accelerate Wound Healing In Vivo","volume":"175","author":"Pfalzgraff","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Vacas, A., Fern\u00e1ndez-Rubio, C., Larrea, E., Pe\u00f1a-Guerrero, J., and Nguewa, P.A. (2020). LmjF.22.0810 from Leishmania major Modulates the Th2-Type Immune Response and Is Involved in Leishmaniasis Outcome. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110452"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jac\/dkac007","article-title":"Effect of Topical Berberine in Murine Cutaneous Leishmaniasis Lesions","volume":"77","author":"Calvo","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"W276","DOI":"10.1093\/nar\/gkac240","article-title":"Search and Sequence Analysis Tools Services from EMBL-EBI in 2022","volume":"50","author":"Madeira","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1126\/science.6701528","article-title":"Identification of an Infective Stage of Leishmania Promastigotes","volume":"223","author":"Sacks","year":"1984","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/acsomega.4c08735","article-title":"Human-Validated Neural Networks for Precise Amastigote Categorization and Quantification to Accelerate Drug Discovery in Leishmaniasis","volume":"10","author":"Paes","year":"2025","journal-title":"ACS Omega"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tang, J., Wennerberg, K., and Aittokallio, T. (2015). What Is Synergy? The Saariselk\u00e4 Agreement Revisited. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00181"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The Toxicity of Poisons Applied Jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent Drug Action in Combination Therapy: Implications for Precision Oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kim, D.H., Chung, H.J., Bleys, J., and Ghohestani, R.F. (2009). Is Paromomycin an Effective and Safe Treatment against Cutaneous Leishmaniasis? A Meta-Analysis of 14 Randomized Controlled Trials. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000381"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/ijo.2008.245","article-title":"Molecular Physiology of Weight Regulation in Mice and Humans","volume":"32","author":"Leibel","year":"2008","journal-title":"Int. J. Obes."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106394","DOI":"10.1016\/j.ijantimicag.2021.106394","article-title":"Artemisinin Elevates Ergosterol Levels of Candida Albicans to Synergise with Amphotericin B against Oral Candidiasis","volume":"58","author":"Zhu","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ced.14919","article-title":"Treatment Options for Leishmaniasis","volume":"47","author":"Pradhan","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous Leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1007\/s00253-020-10856-w","article-title":"Recent Advances and New Strategies on Leishmaniasis Treatment","volume":"104","author":"Roatt","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug Repurposing: A Promising Tool to Accelerate the Drug Discovery Process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"El-Dirany, R., Shahrour, H., Dirany, Z., Abdel-Sater, F., Gonzalez-Gaitano, G., Brandenburg, K., Martinez de Tejada, G., and Nguewa, P.A. (2021). Activity of Anti-Microbial Peptides (Amps) against Leishmania and Other Parasites: An Overview. Biomolecules, 11.","DOI":"10.3390\/biom11070984"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102124","DOI":"10.1016\/j.jddst.2020.102124","article-title":"An Update\u2014Prolonging the Action of Protein and Peptide Drugs","volume":"61","author":"Cao","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.3390\/molecules18044373","article-title":"Chemical Methods for Peptide and Protein Production","volume":"18","author":"Chandrudu","year":"2013","journal-title":"Molecules"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4155\/fmc.09.23","article-title":"Manufacturing Peptides as Active Pharmaceutical Ingredients","volume":"1","author":"Zompra","year":"2009","journal-title":"Future Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1021\/acs.joc.8b03001","article-title":"Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production","volume":"84","author":"Kenworthy","year":"2019","journal-title":"J. Org. Chem."},{"key":"ref_33","first-page":"425","article-title":"Artificial Intelligence Driven Protein Design and Sustainable Nanomedicine for Advanced Theranostics","volume":"60","author":"Esmaeilpour","year":"2026","journal-title":"Bioact. Mater."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1753425909106447","article-title":"Structural Prerequisites for Endotoxic Activity in the Limulus Test as Compared to Cytokine Production in Mononuclear Cells","volume":"16","author":"Gutsmann","year":"2009","journal-title":"Innate Immun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1111\/mec.14267","article-title":"Evolution of Defence Cocktails: Antimicrobial Peptide Combinations Reduce Mortality and Persistent Infection","volume":"26","author":"Zanchi","year":"2017","journal-title":"Mol. Ecol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1128\/AAC.02434-15","article-title":"Combination Effects of Antimicrobial Peptides","volume":"60","author":"Yu","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Duong, L., Gross, S.P., and Siryaporn, A. (2021). Developing Antimicrobial Synergy with AMPs. Front. Med. Technol., 3.","DOI":"10.3389\/fmedt.2021.640981"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"118518","DOI":"10.1016\/j.lwt.2025.118518","article-title":"Separation, Identification and Chelation Mechanism of Novel Zinc-Chelating Peptides from Soybean Protein Enzymatic Hydrolysate","volume":"233","author":"Duan","year":"2025","journal-title":"LWT"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wu, N., Yang, Z., Wu, C., Chen, Y., Chan, Z., and Zeng, R. (2025). Purification and Characterization of Anti-Inflammatory Peptide Fractions from Enzymatic Hydrolysate of Abalone Viscera. Foods, 14.","DOI":"10.3390\/foods14223811"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1038\/s41467-023-42940-w","article-title":"Sequence-Based Prediction of the Intrinsic Solubility of Peptides Containing Non-Natural Amino Acids","volume":"14","author":"Oeller","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1021\/acs.jcim.2c01317","article-title":"Serverless Prediction of Peptide Properties with Recurrent Neural Networks","volume":"63","author":"Ansari","year":"2023","journal-title":"J. Chem. Inf. Model."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/332\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:13:54Z","timestamp":1773119634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["pharmaceutics18030332"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18030332","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}